Actuate Therapeutics Inc (ACTU) Stock Price, Quote & News

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and color...

Industry: Biotechnology

Sector: Healthcare

Phone: 817 887 8455

Website: actuatetherapeutics.com

Address:

1751 River Run, Suite 400, Fort Worth, United States

JohnTrack Jan. 6 at 7:24 PM

$ACTU Positive Patient Outcomes from Phase 1 https://www.rapidticker.com/news/actu-actuate-therapeutics-announces-positive-patient-d9e1b6

0 · Reply

topstockalerts Jan. 6 at 3:49 PM

Actuate Therapeutics reported encouraging Phase 1 results for elraglusib in difficult-to-treat pediatric cancers. The trial showed meaningful clinical activity, including two complete metabolic responses in relapsed/refractory metastatic Ewing sarcoma patients and a complete response in a relapsed/refractory metastatic neuroblastoma patient. In the open-label, multicenter study of 40 pediatric patients with relapsed or refractory cancers, 15 showed clinical responses or disease control. Notably, 10 of 19 patients treated with elraglusib in combination with cyclophosphamide/topotecan achieved positive outcomes. The company highlighted cases of heavily pretreated patients achieving substantial tumor reduction and complete bone marrow response. Actuate plans to advance elraglusib’s clinical development in Ewing sarcoma and potentially neuroblastoma in 2026. $ACTU

0 · Reply

OpenOutcrier Jan. 6 at 2:05 PM

$ACTU (+7.7% pre) Actuate reports responses in pediatric cancer trial https://ooc.bz/l/88737

0 · Reply

Smellmahass Jan. 6 at 12:47 AM

$ACTU So they released this pancreatic data already? Whats this data on the 9th?

0 · Reply

JustGB Jan. 5 at 12:31 PM

$DRTS leading the charge at ASCO GI 2026 (Jan 8-10) with two Alpha DaRT abstracts on pancreatic cancer pilots – feasibility/safety/efficacy + immune markers. Building momentum in this innovative alpha-radiation space for tough cancers. Also watching related plays like $ACTU (Phase 2 data oral/poster), $AMIX (pain mitigation poster), and $BFRG (AI-subtyping poster). Big week ahead for pancreatic oncology!

1 · Reply

JKtech Jan. 5 at 11:17 AM

ASCO GI 2026: What to watch The data is LIVE and Alpha Tau is the standout. Two massive abstracts prove Alpha DaRT is the next frontier in internal oncology: $DRTS - Abstract #1 shows breakthrough safety in advanced Pancreas cancer treatment. Ultra-high dose precision in "inoperable" tumors. Abstract #2 highlights immune markers-turning the tumor into its own vaccine. 31% insider skin-in-the-game + $12 analyst PT. $ACTU - Jan 9 Oral session on Elraglusib. Risk of death reduced by 37% in early looks. The market wants the full survival curves. $RNXT - Abstract #732. Proving their TAMP platform hits the tumor harder with fewer side effects than systemic chemo. $ALPMY - Late-breaking data on Zolbetuximab. Setting the "Precision" ceiling for the Gl sector

1 · Reply

CapitalCycleNavigator Dec. 27 at 7:59 AM

$ACTU Positioning is increasingly shaped by how predictably management executes. Cash discipline will likely dictate investor patience. Credible progress tends to compress risk premiums. Execution quality becomes the defining catalyst from here.

0 · Reply

SuperGreenToday Dec. 19 at 10:56 PM

$ACTU

0 · Reply

TwongStocks Dec. 18 at 1:46 PM

$ACTU Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 https://www.globenewswire.com/news-release/2025/12/18/3207741/0/en/Actuate-Therapeutics-Phase-2-Metastatic-Pancreatic-Cancer-Data-Selected-for-Oral-and-Poster-Presentation-at-ASCO-GI-2026.html Oral Presentation Title: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). Poster Presentation Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B Phase 2 study.

0 · Reply

JohnTrack Dec. 15 at 2:13 PM

$ACTU phase II results https://www.rapidticker.com/news/actu-actuate-therapeutics-announces-publication-of-fa59bf

0 · Reply

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Dec 18, 2025, 8:45 AM EST - 19 days ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

Sep 22, 2025, 8:45 AM EDT - 3 months ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Sep 10, 2025, 8:31 AM EDT - 4 months ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Sep 9, 2025, 4:07 PM EDT - 4 months ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Aug 6, 2025, 8:45 AM EDT - 5 months ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Jul 17, 2025, 8:45 AM EDT - 6 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Jun 24, 2025, 9:15 AM EDT - 7 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Jun 20, 2025, 8:45 AM EDT - 7 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Jun 16, 2025, 8:30 AM EDT - 7 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

May 31, 2025, 4:30 PM EDT - 7 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 8 months ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Apr 23, 2025, 10:24 AM EDT - 9 months ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 17, 2025, 8:00 AM EDT - 9 months ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Feb 6, 2025, 8:00 AM EST - 11 months ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Dec 17, 2024, 8:28 AM EST - 1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Oct 29, 2024, 6:39 PM EDT - 1 year ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

$Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma$

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 5, 2024, 9:10 AM EDT - 1 year ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 17, 2024, 5:10 AM EDT - 1 year ago

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

HCAI TDTH WRD YXT

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

Aug 3, 2024, 12:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

GFL OSTX

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ARDT ARTV CON LINE OS QMMM TWFG

May 28, 2024, 5:34 PM EDT - 1 year ago

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

JohnTrack Jan. 6 at 7:24 PM

$ACTU Positive Patient Outcomes from Phase 1 https://www.rapidticker.com/news/actu-actuate-therapeutics-announces-positive-patient-d9e1b6

0 · Reply

topstockalerts Jan. 6 at 3:49 PM

0 · Reply

OpenOutcrier Jan. 6 at 2:05 PM

$ACTU (+7.7% pre) Actuate reports responses in pediatric cancer trial https://ooc.bz/l/88737

0 · Reply

Smellmahass Jan. 6 at 12:47 AM

$ACTU So they released this pancreatic data already? Whats this data on the 9th?

0 · Reply

JustGB Jan. 5 at 12:31 PM

1 · Reply

JKtech Jan. 5 at 11:17 AM

1 · Reply

CapitalCycleNavigator Dec. 27 at 7:59 AM

0 · Reply

SuperGreenToday Dec. 19 at 10:56 PM

$ACTU

0 · Reply

TwongStocks Dec. 18 at 1:46 PM

0 · Reply

JohnTrack Dec. 15 at 2:13 PM

$ACTU phase II results https://www.rapidticker.com/news/actu-actuate-therapeutics-announces-publication-of-fa59bf

0 · Reply

TwongStocks Dec. 15 at 1:46 PM

$ACTU Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma https://www.globenewswire.com/news-release/2025/12/15/3205465/0/en/Actuate-Therapeutics-Announces-Publication-of-Positive-Phase-II-Clinical-Data-for-Elraglusib-Combined-with-Platinum-Chemotherapy-and-Sequential-Immunotherapy-in-Recurrent-Metastati.html • Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. • Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease

0 · Reply

Stock_Catcher Dec. 15 at 1:45 PM

0 · Reply

TwongStocks Dec. 15 at 12:38 PM

$ACTU Might be a PR this morning.

0 · Reply

JarvisFlow Nov. 19 at 11:31 AM

HC Wainwright & Co. has updated their rating for Actuate Therapeutics ( $ACTU ) to Buy with a price target of 20.

0 · Reply

Markus_Fehnle Oct. 21 at 1:10 PM

$ACTU shouldn´t this fly?!

0 · Reply

BullTradeFinder Oct. 16 at 7:24 PM

🔬 $ACTU Advances Pancreatic Cancer Fight! Actuate Therapeutics has submitted updated clinical data to the FDA & EMA supporting elraglusib’s safety + survival benefit in combo therapy aiming to spark regulatory momentum in late 2025. This is a name to watch with a potential for regulatory approval in future. Communicated-Disclaimer https://stockresearchtoday.com/the-future-of-oncology/

0 · Reply

TheRealShortSqueezy Oct. 16 at 7:15 PM

$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS

2 · Reply

Trader1141 Oct. 16 at 3:19 PM

$ACTU anyone interested? $PRAX

0 · Reply

The_Titan_Traders Oct. 16 at 3:14 PM

$ACTU | PANCREATIC CANCER BREAKTHROUGH IN MOTION 🔬🔥 Actuate Therapeutics ($ACTU) is emerging as one of the most compelling precision-oncology plays in small-cap biotech — targeting one of the deadliest cancers: metastatic pancreatic cancer. In its Phase 2 trial, Actuate delivered remarkable survival data, including a +47% one-year survival rate and a 43% reduction in mortality risk. These kinds of results are rare in PDAC — signaling a genuine therapeutic advance in a field long overdue for innovation. Communicated-Disclaimer: https://chartingdaily.com/Actu

0 · Reply

TheRealShortSqueezy Oct. 16 at 1:43 PM

$ACTU is emerging as a biotech game-changer 🧬 Actuate Therapeutics is developing an innovative cancer therapy that enhances chemotherapy by blocking tumor resistance, giving new hope in the fight against aggressive cancers. Recent data shows its lead drug elraglusib has doubled survival for certain pancreatic cancer patients, signaling a true breakthrough in oncology. 💥 Analyst Targets: ✅ B. Riley Securities: $20 ✅ HC Wainwright: $20 Insider Activity: 💸 2025: Directors added 214,000+ shares — no sales recorded. Technical Setup: 📈 Strong consolidation after last week’s uptrend 📈 Key support: $7.60–$7.75 📈 Breakout watch: $8.X.27 Next Levels to Watch: $9.22 ➡️ $10 ➡️ $10.92 ➡️ $12 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $JNJ $LLY $MRNA $PFE

0 · Reply

BullTradeFinder Oct. 15 at 4:37 PM

$ACTU is turning heads in biotech! After just dropping strong Phase 2 results for its cancer drug, showing major survival gains in pancreatic patients. Just receiving Orphan Drug Designation by the FDA for a disease that has plagued the world. Communicated-Disclaimer chartingdaily.com/Actu

0 · Reply

The_Titan_Traders Oct. 15 at 3:14 PM

$ACTU IS REWRITING THE FUTURE OF PANCREATIC CANCER TREATMENT 🔬 Pancreatic cancer has long been one of the toughest battles in oncology but Actuate Therapeutics ($ACTU) is changing the narrative. 💥 Phase 2 clinical data shows stunning progress: • +47% increase in 1-year survival rates compared to standard outcomes • 43% reduction in risk of death among treated patients • Evidence of strong and durable responses in one of the deadliest cancer types (PDAC) 🔥 Why this matters: Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates in oncology. Any improvement of this magnitude isn’t incremental — it’s transformational. 🚀 Regulatory & Market Edge: • Orphan Drug Designation = accelerated development path and extended exclusivity • Added to the Russell 2000 Index, boosting visibility and institutional demand Disclaimer: https://stockresearchtoday.com/the-future-of-oncology/

0 · Reply

Market Cap	140.16M
Revenue (ttm)	0.00
Net Income (ttm)	-27.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	94,600
Avg Vol	72,640
Day's Range	N/A - N/A
Shares Out	23.24M
Stochastic %K	80%
Beta	-0.15
Analysts	Strong Sell
Price Target	$21.67